IP Library Granted Patent US 8,883,837
Granted Patent B2
US 8,883,837 · App. 12/140,686 · Granted Nov 11, 2014

Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,837
App. No.
12/140,686
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

Claims (79)

1. A compound having the formula

an addition salt, quaternary amine, or a stereochemically isomeric form thereof, wherein

G is a direct bond or C 1-10 alkanediyl optionally substituted with one or more substituents individually selected from the group of substituents consisting of hydroxy, C 1-6 alkyloxy, Ar 1 C 1-6 alkyloxy, C 1-6 alkylthio, Ar 1 C 1-6 alkylthio, HO(—CH 2 —CH 2 —O) n —, C 1-6 alkyloxy(—CH 2 —CH 2 —O) n — or Ar 1 C 1-6 alkyloxy(—CH 2 —CH 2 —O) n —;

R 1 is a pyridyl,

wherein said pyridyl may optionally be substituted with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxyC 1-6 alkyl, Ar 1 , Ar 1 C 1-6 alkyl, Ar 1 C 1-6 alkyloxy, hydroxyC 1-6 alkyl, mono-or di(C 1-6 alkyl)amino, mono-or di(C 1-6 alkyl)aminoC 1-6 alkyl, polyhaloC 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkyl-SO 2 —NR 5c —, Ar 1 —SO 2 —NR 5c —, C 1-6 alkyloxycarbonyl, —C(═O)—NR 5c R 5d , HO(—CH 2 —CH 2 —O) n —, halo(—CH 2 —CH 2 —O) n —, C 1-6 alkyloxy(—CH 2 —CH 2 —O) n —, Ar 1 C 1-6 alkyloxy(—CH 2 —CH 2 —O) n — and mono-or di(C 1-6 alkyl)amino(—CH 2 —CH 2 —O) n —;

each n independently is 1, 2, 3 or 4;

each t independently is 0, 1 or 2;

Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 wherein

R 7 is C 1-6 alkyl substituted with a heterocycle or R 7 is C 1-6 alkyl substituted with both a radical —OR 8 and a heterocycle, wherein said heterocycle is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxyC 1-6 alkyl, aminocarbonylC 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)aminosulfonyl;

R 8 is hydrogen, C 1-6 alkyl or Ar 1 C 1-6 alkyl;

one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(═Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen;

wherein

═Z is ═O, ═CH—C(═O)—NR 5a R 5b , ═CH 2 , ═CH—C 1-6 alkyl, ═N—OH or ═N—O—C 1-6 alkyl; and

the optional substituents on C 1-6 alkyl and C 2-6 alkenyl can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydroxy, cyano, halo, nitro, N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, Het, Ar 2 , C 1-6 alkyloxy, C 1-6 alkyl-S(═O) t , Ar 2 oxy, Ar 2 —S(═O) t , Ar 2 C 1-6 alkyloxy, Ar 2 C 1-6 alkyl-S(═O) t , Het-oxy, Het-S(═O) t , HetC 1-6 alkyloxy, HetC 1-6 alkyl-S(═O) t , carboxyl, C 1-6 alkyloxycarbonyl and —C(═Z)Ar 2 ;

in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen;

in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen;

R 4a and R 4b can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydrogen, C 1-6 alkyl, Ar 2 C 1-6 alkyl, (Ar 2 )(hydroxy)C 1-6 alkyl, Het-C 1-6 alkyl, hydroxyC 1-6 alkyl, mono- and di-(C 1-6 alkyloxy)C 1-6 alkyl, (hydroxyC 1-6 alkyl)oxyC 1-6 alkyl, Ar 1 C 1-6 alkyloxy-C 1-6 alkyl, dihydroxyC 1-6 alkyl, (C 1-6 alkyloxy)(hydroxy)C 1-6 alkyl, (Ar 1 C 1-6 alkyloxy)(hydroxy)C 1-6 alkyl, Ar 1 oxy-C 1-6 alkyl, (Ar 1 oxy)(hydroxy)-C 1-6 alkyl, aminoC 1-6 alkyl, mono- and di(C 1-6 alkyl)amino-C 1-6 alkyl, carboxylC 1-6 alkyl, C 1-6 alkyloxycarbonylC 1-6 alkyl, aminocarbonylC 1-6 alkyl, mono- and di(C 1-6 alkyl)aminocarbonylC 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, (C 1-4 alkyloxy) 2 P(═O)—C 1-6 alkyl, (C 1-4 alkyloxy) 2 P(═O)—O—C 1-6 alkyl, aminosulfonyl- C 1-6 alkyl, mono- and di(C 1-6 alkyl)aminosulfonyl-C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 2 carbonyl, Het-carbonyl, Ar 2 C 1-6 alkylcarbonyl, Het-C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, aminosulfonyl, mono- and di(C 1-6 alkyl)aminosulfonyl, Ar 2 sulfonyl, Ar 2 C 1-6 alkylsulfonyl, Ar 2 , Het, Het-sulfonyl, HetC 1-6 alkylsulfonyl;

R 5 is hydrogen or C 1-6 alkyl;

R 5a and R 5b can be the same or can be different relative to one another, and are each independently hydrogen or C 1-6 alkyl; or

R 5a and R 5b taken together may form a bivalent radical of formula —(CH 2 ) s — wherein s is 4 or 5;

R 5c and R 5d can be the same or can be different relative to one another, and are each independently hydrogen or C 1-6 alkyl; or

R 5c and R 5d taken together may form a bivalent radical of formula —(CH 2 ) s — wherein s is 4 or 5;

Ar 1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C 1-6 alkyl, hydroxyC 1-6 alkyl, polyhaloC 1-6 alkyl, and C 1-6 alkyloxy;

Ar 2 is phenyl, phenyl annelated with C 5-7 cycloalkyl, or phenyl substituted with 1 or more, such as 2, 3, 4 or 5, substituents selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl—SO 2 —, —N(R 6a R 6b ), polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, polyhaloC 1-6 alkylthio, R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-10 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl, R 6c —C(═O)—NR 6b —, R 6c —C(═O)—O—, R 6c —C(═O)—NR 6b —C 1-6 alkyl, R 6c —C(═O)—O—C 1-6 alkyl, N(R 6a R 6b )—S(═O) 2 —, or H 2 N—C(═NH)—;

R 6a is hydrogen, C 1-6 alkyl, Ar 1 , Ar 1 C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 carbonyl, Ar 1 C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, Ar 1 sulfonyl, Ar 1 C 1-6 alkylsulfonyl, C 1-6 alkyloxyC 1-6 alkyl, aminoC 1-6 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, hydroxyC 1-6 alkyl, (carboxyl)-C 1-6 alkyl, (C 1-6 alkyloxycarbonyl)-C 1-6 alkyl, aminocarbonylC 1-6 alkyl, mono- and di(C 1-6 alkyl)aminocarbonylC 1-6 alkyl, aminosulfonyl-C 1-6 alkyl, mono- and di(C 1-6 alkyl)aminosulfonyl-C 1-6 alkyl, Het, Het-C 1-6 alkyl, Het-carbonyl, Het-sulfonyl, or Het-C 1-6 alkylcarbonyl;

R 6b is hydrogen, C 1-6 alkyl, Ar 1 or Ar 1 C 1-6 alkyl;

R 6c is C 1-6 alkyl, Ar 1 or Ar 1 C 1-6 alkyl;

Het is a heterocycle being selected from tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidinonyl, furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, tetrahydroquinolinyl, quinolinyl, isoquinolinyl, benzodioxanyl, benzodioxolyl, indolinyl, or indolyl, each of said heterocycle may optionally be substituted with oxo, amino, Ar 1 , C 1-4 alkyl, aminoC 1-4 alkyl, Ar 1 C 1-4 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, mono- or di(C 1-6 alkyl)amino, (hydroxyC 1-6 alkyl)amino, and optionally further with one or two C 1-4 alkyl radicals.

2. A compound according to claim 1 wherein the compound has the formula:

wherein

Alk 1 is C 1-6 alkanediyl;

R 7a is a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine;

wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)aminosulfonyl.

3. A compound according to claim 1 wherein the compound has the formula:

wherein

Alk 1 is C 1-6 alkanediyl and R 7a is a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydro-oxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydro-thiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)aminosulfonyl.

4. A compound according to claim 1 wherein the compound has the formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is-a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)-aminosulfonyl.

5. A compound according to claim 1 wherein the compound has the formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)-aminosulfonyl; and

R 9 , R 10 and R 11 each independently are selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl-SO 2 —, —N(R 6a R 6b ), polyhalo-C 1-6 alkyl, polyhaloC 1-6 alkyloxy, polyhaloC 1-6 alkylthio, R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl, R 6c —C(═O)—NR 6b —, R 6c —C(═O)—O—, R 6c —C(═O)—NR 6b —C 1-6 alkyl, R 6c —C(═O)—O—C 1-6 alkyl, N(R 6a R 6b )—S(═O) 2 —, or H 2 N—C(═NH)—;

and Alk is C 1-6 alkanediyl.

6. A compound according to claim 1 wherein the compound has the formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl, and mono- or di(C 1-4 alkyl)-aminosulfonyl; R 9 , R 10 and R 11 each independently are selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl-SO 2 —, —N(R 6a R 6b ), polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, polyhaloC 1-6 alkylthio, R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl, R 6c —C(═O)—NR 6b —, R 6c —C(═O)—O—, R 6c —C(═O)—NR 6b —C 1-6 alkyl, R 6c —C(═O)—O—C 1-6 alkyl, N(R 6a R 6b )—S(═O) 2 —, or H 2 N—C(═NH)—; and Alk is C 1-6 alkanediyl.

7. A compound according to claim 1 wherein the compound has the formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is—a heterocycle which is selected from the group consisting oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)-aminosulfonyl; R 9 and R 10 each independently are selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl-SO 2 —, —N(R 6a R 6b ), polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, polyhaloC 1-6 alkylthio, R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl, R 6c —C(═O)—NR 6b —, R 6c —C(═O)—O—, R 6c —C(═O)—NR 6b —C 1-6 alkyl, R 6c —C(═O)—O—C 1-6 alkyl, N(R 6a R 6b )—S(═O) 2 —, or H 2 N—C(═NH)—; and Alk is C 1-6 alkanediyl; and

R 6a is hydrogen, C 1-6 alkyl, Ar 1 , Ar 1 C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 carbonyl, Ar 1 C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, Ar 1 sulfonyl, Ar 1 C 1-6 alkylsulfonyl, C 1-6 alkyloxyC 1-6 alkyl, aminoC 1-6 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, hydroxyC 1-6 alkyl, (carboxyl)-C 1-6 alkyl, (C 1-6 alkyloxycarbonyl)-C 1-6 alkyl, aminocarbonylC 1-6 alkyl, mono- and di(C 1-6 alkyl)aminocarbonylC 1-6 alkyl, aminosulfonyl-C 1-6 alkyl, mono- and di(C 1-6 alkyl)aminosulfonyl-C 1-6 alkyl, Het, Het-C 1-6 alkyl, Het-carbonyl, Het-sulfonyl, or Het-C 1-6 alkylcarbonyl; and

R 6b is hydrogen, C 1-6 alkyl, Ar 1 or Ar 1 C 1-6 alkyl.

8. A compound according to claim 1 wherein the compound has the formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is—a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)-aminosulfonyl; R 9 and R 10 each independently are selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 -alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl-SO 2 —, —N(R 6a R 6b ), polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, polyhaloC 1-6 alkylthio, R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl R 6c —C(═O)—NR 6b —, R 6c —C(═O)—O—, R 6c —C(═O)—NR 6b —C 1-6 alkyl, R 6c —C(═O)—O—C 1-6 alkyl, N(R 6a R 6b )—S(═O) 2 —, or H 2 N—C(═NH)—and Alk is C 1-6 alkanediyl; and R 6a is hydrogen, C 1-6 alkyl, Ar 1 , Ar 1 C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 carbonyl, Ar 1 C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, Ar 1 sulfonyl, Ar 1 C 1-6 alkylsulfonyl, C 1-6 alkyloxyC 1-6 alkyl, aminoC 1-6 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, hydroxyC 1-6 alkyl, (carboxyl)-C 1-6 alkyl, (C 1-6 alkyloxycarbonyl)-C 1-6 alkyl, aminocarbonylC 1-6 alkyl, mono- and di(C 1-6 alkyl)aminocarbonylC 1-6 alkyl, aminosulfonyl-C 1-6 alkyl, mono- and di(C 1-6 alkyl)aminosulfonyl-C 1-6 alkyl, Het, Het-C 1-6 alkyl, Het-carbonyl, Het-sulfonyl, or Het-C 1-6 alkylcarbonyl; and R 6b is hydrogen, C 1-6 alkyl, Ar 1 or Ar 1 C 1-6 alkyl.

9. A compound according to claim 1 wherein the compound has the formula:

or of formula:

wherein Alk 1 is C 1-6 alkanediyl and R 7a is—a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and 1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy, carboxyl, C 1-4 alkyloxycarbonyl, aminocarbonyl, mono- or di(C 1-4 alkyl)-aminocarbonyl, C 1-4 alkylcarbonylamino, aminosulfonyl and mono- or di(C 1-4 alkyl)-aminosulfonyl.

10. A compound according to claim 2 , wherein R 7a is a heterocycle selected from the group consisting of oxazolidine, thiazolidine, morpholinyl, thiomorpholinyl, hexahydrooxazepine, or hexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxyC 1-6 alkyl, or aminocarbonylC 1-6 alkyl.

11. A compound according to claim 2 , wherein R 7a is a heterocycle, wherein said heterocycle is oxazolidine, thiazolidine, morpholinyl or thiomorpholinyl, wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C 1-6 alkyl, hydroxy-C 1-6 alkyl, or aminocarbonylC 1-6 alkyl.

12. A compound according to claim 2 , wherein R 7a is morpholinyl.

13. A compound according to claim 5 , wherein Alk is methylene.

14. A compound according to claim 2 , wherein Alk 1 is C 1-4 alkanediyl.

15. A compound according to claim 5 , wherein R 9 , R 10 and R 11 are each independently selected from halo, cyano, C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, Ar 1 , Het, R 6b —O—, R 6b —S—, R 6c —SO 2 —, R 6b —O—C 1-6 alkyl-SO 2 —, —N(R 6a R 6b ), CF 3 , R 6c —C(═O)—, R 6b —O—C(═O)—, N(R 6a R 6b )—C(═O)—, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6c —C(═O)—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, N(R 6a R 6b )—C(═O)—C 1-6 alkyl and R 6c —C(═O)—NR 6b —, or H 2 N—C(═NH)—.

16. A compound according to claim 5 , wherein R 9 , R 10 , and R 11 are each independently selected from C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, R 6b —O—C 3-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 3-6 alkynyl, R 6b —O—C 1-6 alkyl, R 6b —S—C 1-6 alkyl, R 6c —S(═O) 2 —C 1-6 alkyl, N(R 6a R 6b )—C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl and N(R 6a R 6b )—C(═O)—C 1-6 alkyl.

17. A compound according to claim 5 , wherein R 9 , R 10 , R 11 are each independently selected from C 1-6 alkyl, Het-C 1-6 alkyl, Ar 1 —C 1-6 alkyl, cyanoC 1-6 alkyl, C 2-6 alkenyl, cyanoC 2-6 alkenyl, C 2-6 alkynyl, cyanoC 2-6 alkynyl, R 6b —O—C 1-6 alkyl, amino-S(═O) 2 —C 1-6 alkyl, R 6b —O—C(═O)—C 1-6 alkyl, amino-C(═O)—C 1-6 alkyl, mono- and diamino-C(═O)—C 1-6 alkyl.

18. A compound according to claim 5 , wherein R 9 , R 10 , R 11 are each independently C 1-6 alkyl or R 6b —O—C 1-6 alkyl; and R 10 and/or R 11 may also be hydrogen.

19. A compound according to claim 1 , wherein G is C 1-10 alkanediyl.

20. A compound according to claim 1 , wherein G is methylene.

21. A compound according to claim 1 wherein R 1 is

pyridyl; wherein the pyridyl may be substitude with 1, 2 or 3 substituents independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxyC 1-6 alkyl, Ar 1 , Ar 1 C 1-6 alkyl, Ar 1 C 1-6 alkyloxy, hydroxyC 1-6 alkyl, mono- or di(C 1-6 alkyl)amino, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, polyhaloC 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkyl-SO 2 —NR 5c —, Ar 1 —SO 2 —NR 5c —, C 1-6 alkyloxycarbonyl, —C(═O)—NR 5c R 5d , HO(—CH 2 —CH 2 —O) n —, halo(—CH 2 —CH 2 —O) n —, C 1-6 alkyloxy(—CH 2 —CH 2 —O) n —, Ar 1 C 1-6 alkyloxy(—CH 2 —CH 2 —O) n — and mono- or di(C 1-6 alkyl)amino(—CH 2 —CH 2 —O) n .

22. A compound according to claim 1 wherein R 1 is pyridyl, wherein the pyridyl may optionally be substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C 1-6 alkyl, C 1-6 alkyloxy, Ar 1 C 1-6 alkyloxy, or (C 1-6 alkyloxy)C 1-6 alkyloxy.

23. A compound according to claim 1 wherein R 1 is pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C 1-6 alkyl, benzyloxy or C 1-6 alkyloxy.

24. A compound according to claim 1 wherein R 1 is pyridyl optionally substituted with one or two radicals selected from hydroxy or C 1-6 alkyl.

25. A compound according to claim 1 , wherein, where applicable, one of R 2a and R 3a is selected from —N(R 4a R 4b ), (R 4a R 4b )N—CO—, or C 1-6 alkyl substituted with one or two substituents selected from hydroxy, cyano, Ar 2 , Het or —N(R 4a R 4b ) and

C 2-6 alkenyl substituted with cyano or Ar 2 ; and the other one of R 2a and R 3a is hydrogen; and

in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen;

in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen.

26. A compound according to claim 1 , wherein, where applicable, one of R 2a and R 3a is selected from (R 4a R 4b )N—CO—; or C 1-6 alkyl optionally substituted with hydroxy, Ar 2 , Het or —N(R 4a R 4b ); and C 2-6 alkenyl substituted with Ar 1 ; and the other one of R 2a and R 3a is hydrogen; or

in case R 2a is different from hydrogen then R 2b is hydrogen or C 1-6 alkyl and R 3b is hydrogen;

in case R 3a is different from hydrogen then R 3b is hydrogen or C 1-6 alkyl and R 2b is hydrogen;

Ar 2 , Het, R 4a and R 4b are as in the definitions of the compounds of formula (I) or as in any subgroup specified herein.

27. A compound according to claim 25 , wherein, where applicable, R 2b and R 3b are both hydrogen.

28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a compound as described in claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded Feb 27, 2014
From: TIBOTEC, LLC
To: TIBOTEC, LLC
Reel/Frame 032364/0233 →